A Nurse Risk Manager Consultant visited the facility for two days to abstract information and review the data.
The periods selected for pre- and post-Novaerus review were January through August of 2013 and 2014. Comparison of like periods in both years reduces the risk of skewed data related to seasonal variances.
In the period after implementation of the NV900 units in selected rooms and areas, the total number of nosocomial respiratory infections at CCCC decreased from 29 to 14, a 51.72% reduction.
About Us
Novaerus is on a mission to reduce indoor airborne pollutants that lead to infection, allergies, asthma, and odour.
The patented plasma nanotechnology used in Novaerus portable devices was invented in Ireland in 2006.
Novaerus Devices
Stay Connected to Novaerus
To keep up to date with all developments and for the latest research and scientifically proven results please follow us on LinkedIn, Facebook and Youtube.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.